Sona Nanotech To Host Investor Webinar To Discuss Clinical Study

Executive Summary

• Sona Nanotech Inc. will host a live investor webinar on Monday, October 20, 2025 at noon EDT to discuss its first‑in‑human, early feasibility clinical study of Targeted Hyperthermia™ therapy.
• The study enrolls ten advanced‑stage melanoma patients who have not responded to standard immunotherapy, providing the company an opportunity to present early clinical data and trial progress.
• A recording of the webinar will be posted on Sona’s website for later viewing by investors and other interested parties.

Key Details

• Webinar Date & Time: Monday, October 20, 2025 at 12:00 PM EDT.
• Registration Link: http://bit.ly/3JcFls5.
• Study Focus: First‑in‑human, early feasibility clinical study of Targeted Hyperthermia™ (photothermal cancer therapy) for solid tumors.
• Patient Cohort: Ten advanced‑stage melanoma patients who are refractory to standard immunotherapy.
• Purpose of Webinar: To discuss trial design, enrollment status, anticipated timelines, and preliminary expectations for safety and efficacy data.
• Recording Availability: A full recording will be uploaded to the Investor Information section of Sona Nanotech’s website after the live event.
• Contact for Inquiries: David Regan, CEO – +1‑902‑442‑0653 – [email protected].

Notable Quotes

(No direct quotes were provided in the release.)